Nurix Therapeutics clinical trials
Nurix Therapeutics is the lead sponsor of 6 current clinical trials in our USA, UK, France, Italy, Poland, Spain, Netherlands and Switzerland registers. 6 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are Bexobrutideg, Obinutuzumab and Paclitaxel. The most-studied condition is Chronic Lymphocytic Leukemia (CLL).
ClinicalTrials.gov trials by status
Trials by phase
Clinical trials sponsored by Nurix Therapeutics
6 on ClinicalTrials.gov| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
NCT07516093 · B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Drugs: Bexobrutideg, Pirtobrutinib |
Phase 3 | Recruiting | 2026-08 | USA |
|
A Study of NX-1607 in Adults With Advanced Malignancies
NCT05107674 · Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer
Drug: Paclitaxel |
Phase 1 | Recruiting | 2021-09 | UK, USA |
|
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
NCT07221500 · Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Drug: Bexobrutideg |
Phase 2 | Recruiting | 2025-10 | UK, USA, France, Italy, Poland |
|
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
NCT05131022 · Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL)
Drug: Bexobrutideg |
Phase 1 | Recruiting | 2022-04 | UK, USA, France, Spain, Italy, Netherlands, Poland, Switzerland |
|
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
NCT04830137 · Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia (WM)
|
Phase 1 | Recruiting | 2021-05 | USA |
|
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
NCT07520006 · B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
|
Phase 1/2 | Recruiting | 2026-09 | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs in Nurix Therapeutics trials
6 compoundsDrugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
Conditions in Nurix Therapeutics trials
13 conditionsBy trial register
A trial with sites in more than one country appears in each of those registers.
Questions about Nurix Therapeutics trials
How many clinical trials does Nurix Therapeutics sponsor?
Nurix Therapeutics is the lead sponsor of 6 current trials on ClinicalTrials.gov in our USA, UK, France, Italy, Poland, Spain, Netherlands and Switzerland registers, as of the registry sync on 11 November 2026. Completed and withdrawn studies are not counted.
Are Nurix Therapeutics trials recruiting?
Yes. 6 of its 6 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Which drugs is Nurix Therapeutics testing?
Its current trials name 6 drugs and biologicals as interventions. The most frequent are Bexobrutideg (4), Obinutuzumab (1), Paclitaxel (1), Pirtobrutinib (1) and Rituximab (1). The number in brackets is how many of its trials name each drug.
Where does this information come from?
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
How this page is built
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
- EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 11 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.